Flagship explainer

What drives Orchestra BioMed Holdings, Inc.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−122%Tax burden100%net income ÷ pretax incomeInterest burden102%pretax ÷ operating incomeOperating margin−155%operating income ÷ revenueAsset turnover0.35×revenue ÷ average assetsEquity multiplier2.21×average assets ÷ average equityAs of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$52.7MFY2025
Income before tax−$52.7MFY2025
Operating income−$51.8MFY2025
$33.5MFY2025
Ending assets$115MFY2025
Beginning assets$76.2MFY2024
$53.6MFY2025
$33MFY2024
Source: · event Dec 31, 2025 · retrieved Sep 19, 2026 · annual-row source set
Embed this chart

View the full Orchestra BioMed Holdings, Inc. analysis at Buy Like Buffett